Exane BNP Paribas analyst Richard Parkes upgraded Novo Nordisk (NVO) to Outperform from Neutral with a DKK 930 price target The firm believes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback